SCHEMBL1025871

SCHEMBL1025871

CCOC(=O)CN(CC(=O)OCC)c1cc(C(C)=O)ccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
CREBBP Q92793 1/20 0.40
TSHR P16473 2/20 0.39
CA12 O43570 3/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
NLRP3 Q96P20 1/20 0.37
CA7 P43166 2/20 0.36
CA14 Q9ULX7 2/20 0.36
POLB P06746 1/20 0.36
CRHR1 P34998 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
PPARG P37231 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1026492 0.88 CREBBP (0.40) ALDH1A1CREBBPTSHRCA12CA1
SCHEMBL1026653 0.88 ALDH1A1 (0.52) ALDH1A1TSHRCA12CA1CA2
SCHEMBL1027895 0.88 ALDH1A1 (0.46) ALDH1A1TSHRCA12CA1CA2
SCHEMBL1025793 0.87 ALDH1A1 (0.45) ALDH1A1TSHRCA12CA1CA2
SCHEMBL1024063 0.85 ALDH1A1 (0.44) ALDH1A1TSHRCA12CA1CA2
SCHEMBL1028604 0.85 ALDH1A1 (0.43) ALDH1A1CA12CA1CA2CA9
SCHEMBL1027534 0.83 NPC1 (0.46) ALDH1A1TDP1SMN1; SMN2POLBMEN1
SCHEMBL1025939 0.82 ALDH1A1 (0.47) ALDH1A1TSHRCA12CA1CA2
SCHEMBL1026486 0.81 ALDH1A1 (0.47) ALDH1A1TDP1SMN1; SMN2POLBCRHR1
SCHEMBL1025911 0.81 NPSR1 (0.41) ALDH1A1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 ALDH1A1 180/4885CREBBP 48/4885TSHR 4241/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 ALDH1A1 600/4885CREBBP 3156/4885TSHR 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.